CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma

Abstract Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y. Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/032afe6e96c44360aab91f2fc7cc11a0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:032afe6e96c44360aab91f2fc7cc11a0
record_format	dspace
spelling	oai:doaj.org-article:032afe6e96c44360aab91f2fc7cc11a02021-12-02T17:23:51ZCLDN15 is a novel diagnostic marker for malignant pleural mesothelioma10.1038/s41598-021-91464-02045-2322https://doaj.org/article/032afe6e96c44360aab91f2fc7cc11a02021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91464-0https://doaj.org/toc/2045-2322Abstract Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives or false negatives, a novel mesothelial positive marker is required. In the present study, we screened 25 claudins and found that claudin-15 is expressed in the mesothelial cells. We made new rat anti-human claudin-15 (CLDN15) monoclonal antibodies that selectively recognize CLDN15, and investigated whether CLDN15 is a good positive marker for malignant pleural mesotheliomas (MPMs) using MPM tissue samples by immunohistochemistry and semi-quantification of the expression level using an immunoreactive score (IRS) method. Of 42 MPM samples, 83% were positive for CLDN15. The positive ratio was equal to or greater than other positive markers for MPMs including calretinin (81%), WT-1 (50%), and D2-40 (81%). In 50 lung adenocarcinoma sections, four cases were positive for CLDN15 and the specificity (92%) was comparable with other markers (90–100%). Notably, CLDN15 was rarely detected in 24 non-mesothelial tumors in the tissue microarray (12/327 cases). In conclusion, CLDN15 can be used in the clinical setting as a positive marker for MPM diagnosis.Masayuki WatanabeTomohito HigashiKana OzekiAtsuko Y. HigashiKotaro SugimotoHayato MineHironori TakagiYuki OzakiSatoshi MutoNaoyuki OkabeYuki MatsumuraTakeo HasegawaYutaka ShioHiroyuki SuzukiHideki ChibaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Masayuki Watanabe Tomohito Higashi Kana Ozeki Atsuko Y. Higashi Kotaro Sugimoto Hayato Mine Hironori Takagi Yuki Ozaki Satoshi Muto Naoyuki Okabe Yuki Matsumura Takeo Hasegawa Yutaka Shio Hiroyuki Suzuki Hideki Chiba CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
description	Abstract Malignant mesothelioma is a cancer with a poor survival rate. It is difficult to diagnose mesotheliomas because they show a variety of histological patterns similar to those of various other cancers. However, since currently used positive markers for mesotheliomas may show false positives or false negatives, a novel mesothelial positive marker is required. In the present study, we screened 25 claudins and found that claudin-15 is expressed in the mesothelial cells. We made new rat anti-human claudin-15 (CLDN15) monoclonal antibodies that selectively recognize CLDN15, and investigated whether CLDN15 is a good positive marker for malignant pleural mesotheliomas (MPMs) using MPM tissue samples by immunohistochemistry and semi-quantification of the expression level using an immunoreactive score (IRS) method. Of 42 MPM samples, 83% were positive for CLDN15. The positive ratio was equal to or greater than other positive markers for MPMs including calretinin (81%), WT-1 (50%), and D2-40 (81%). In 50 lung adenocarcinoma sections, four cases were positive for CLDN15 and the specificity (92%) was comparable with other markers (90–100%). Notably, CLDN15 was rarely detected in 24 non-mesothelial tumors in the tissue microarray (12/327 cases). In conclusion, CLDN15 can be used in the clinical setting as a positive marker for MPM diagnosis.
format	article
author	Masayuki Watanabe Tomohito Higashi Kana Ozeki Atsuko Y. Higashi Kotaro Sugimoto Hayato Mine Hironori Takagi Yuki Ozaki Satoshi Muto Naoyuki Okabe Yuki Matsumura Takeo Hasegawa Yutaka Shio Hiroyuki Suzuki Hideki Chiba
author_facet	Masayuki Watanabe Tomohito Higashi Kana Ozeki Atsuko Y. Higashi Kotaro Sugimoto Hayato Mine Hironori Takagi Yuki Ozaki Satoshi Muto Naoyuki Okabe Yuki Matsumura Takeo Hasegawa Yutaka Shio Hiroyuki Suzuki Hideki Chiba
author_sort	Masayuki Watanabe
title	CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
title_short	CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
title_full	CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
title_fullStr	CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
title_full_unstemmed	CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
title_sort	cldn15 is a novel diagnostic marker for malignant pleural mesothelioma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/032afe6e96c44360aab91f2fc7cc11a0
work_keys_str_mv	AT masayukiwatanabe cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT tomohitohigashi cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT kanaozeki cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT atsukoyhigashi cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT kotarosugimoto cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT hayatomine cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT hironoritakagi cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT yukiozaki cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT satoshimuto cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT naoyukiokabe cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT yukimatsumura cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT takeohasegawa cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT yutakashio cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT hiroyukisuzuki cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma AT hidekichiba cldn15isanoveldiagnosticmarkerformalignantpleuralmesothelioma
_version_	1718380947420741632

CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma

Ejemplares similares